EXHIBIT 220

EVANSTON NORTHWESTERN HEALTHCARE

OMEGA
Corporate and Occupational Health Services

2150 Pfingsten Road
Suite 3000
Glenview, Illinois 60026-1314
(847) 657-1700
(847) 657-1715 fax

April 25, 2008

Sarita Thapar, PharmD.
Director, US Medical Affairs
ACTAVIS LLC
200 Elmora Avenue
Elizabeth, NJ 07207

Sent via Federal Express Overnight – Tracking # 791053281809

Re: Health Hazard Evaluations

Dear Sarita:

Please find enclosed the [redacted] HHE's that you have Dr. Leikin review. As we discussed the [redacted] is still being typed up and yet to be sent for signature by your office.

If you should have any questions please do not hesitate to contact our office.

Sincerely,

Julie Licata

Julie Licata
Administrative Assistant
to Jerrold B. Leikin MD
Director of Medical Toxicology
Evanston Northwestern Healthcare – OMEGA

Enclosures



actavis
creating value in pharmaceuticals

Memo

To	File	Date	18-Apr-08
From	Jerrold B. Leikin MD –Director of Medical Toxicology ENH OMEGA		
Subject	Health Hazard Evaluation – Digoxin Tabs 0.125 mg	Reference	Investigation log # 07-093

Actavis Medical Affairs contracted Jerrold B. Leikin MD. to perform a Health Hazard Evaluation (HHE) for the subject drug product. Specifically, to evaluate the impact of Digoxin Tabs 0.125 mg that were had a thickness approximately double to that required ; this issue was found during packaging/filling operations on packaging line # 405 in November, 2007 (batch # 70924A1).

Therapeutic use: Cardiac inotropic and anti-arrhythmic agent indicated for the treatment of mild to moderate heart failure.

Root cause evaluation noted that the tablets found with double thickness might have been produced during the re-adjustment at start up. It was believed possible that the tablets might have been stuck in the tablet de-duster or metal detector and was not noticed by the press operator.

Clinical conclusion: Potential risks to the patient depend upon the constituency of the tablets. If the tablets contain double the dose (0.250 mg), then it can be expected that digitalis toxicity can occur in individuals taking daily doses or in patients with renal insufficiency. Toxicity can include nausea, vomiting, dizziness, low blood pressure, cardiac instability and bradycardia. Death can result from excessive digitalis intake.

If the increased thickness is due to clinically inert substances, then a decreased amount of digitalis may be absorbed, leading to exacerbation of the underlying cardiac disease (congestive heart failure and arrhythmia) due to lack of therapeutic efficacy.

Based upon US Actavis Medical Affairs' internal review of domestic spontaneously reported adverse events for the time period of January 1, 2005 until March 31, 2008, a pattern of events were not identified for this product related or unrelated to known adverse events. Serious adverse events implies that such events are associated with death, a life-threatening event, caused permanent disability or damage, led to hospitalization, involved a congenital abnormality, or may have caused an important medical event. In this review, eleven adverse events were noted. Reported adverse event cases do not imply a direct cause-effect relationship of the product and the event since these are spontaneously reported cases that may have multiple confounding factors reported by known and unknown qualified sources.

Dates	ID Number	Expedited/Periodic	Adverse Event	Domestic Spontaneous (lot number and Exp date)
26-MAY-2006	2006AL001331	PERIODIC	Vision blurred	unknown
05-JUL-2006	2006AL001672	PERIODIC	Rash, Pruritus	unknown
03-AUG-2006	2006AL002107	PERIODIC	Diarrhoea, Fluid retention	unknown
11-SEP-2006	2006AL002747	PERIODIC	Blood pressure increased	unknown
29-SEP-2006	2006AL002987	EXPEDITED	Cardiac failure acute, Cardiac failure congestive	unknown
16-OCT-2006	2006AL003173	EXPEDITED	Tremor, Gait abnormal,	unknown

actavis
creating value in pharmaceuticals

			Paraesthesia	
05-MAR-2007	2007AL000909	PERIODIC	Drug ineffective, Dysgeusia, Atrial fibrillation	60400A1
10-MAY-2007	2007AL001896	PERIODIC	Hyperaesthesia, Burning sensation, Erythema, Cough, Hoarseness	unknown
01-JUN-2007	2007AL002191	PERIODIC	Asthenia, Fatigue, Visual disturbance	unknown
10-JAN-2008	2008AL000238	PERIODIC	Medication error	unknown
20-MAR-2008	2008AL001820	PERIODIC	Heart rate increased, Drug ineffective	unknown

Jerrold B. Leikin MD, Director of Medical Toxicology ENH OMEGA

Copy To:

Jasmine Shah, Vice President, US Regulatory Affairs
Phyllis Lambridis, Vice President, US Quality & Compliance
Tony Delicato, Site Director, Quality Assurance
Sarita Thapar, Director of Medical Affairs